Wright Investors Service Comprehensive Report for Salix Pharmaceuticals, Ltd.
06 Mar 2014
Available for Immediate Download
Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio tables (Accounting, Asset Utilization, Employee Efficiency, Fixed Charges Coverage, Leverage Analysis, Liquidity Analysis, Per-share Data and Profitability Analysis) and proprietary Wright Quality Rating analyses tables. The Wright Quality Rating, a measure of corporate risk, examines the liquidity of the stock, financial strength, profitability and corporate growth characteristics of Salix Pharmaceuticals, Ltd. There is a textual review of the financial results of Salix Pharmaceuticals, Ltd. versus Myriad Genetics Inc, United Therapeutics Corporation and Impax Laboratories, Inc. The comparative analysis of these companies compares Sales (sales, sales growth and sales per employee), Company Valuations (Price/Earnings, Price/Book, Price/Sales and 52-Week Price Change) and Financial Position (Long-term Debt/Equity). Also included for Salix Pharmaceuticals, Ltd. are the Company Description, Recent Stock Performance, Profitability Analysis, Dividend Analysis, and Key Data Items (Ticker, Major Industry, Sub-Industry, Fiscal Year End Month, Employees, Share Type, Market Capitalization, Total Shares Outstanding and Number of Closely Held Shares.) Additional research for Salix Pharmaceuticals, Ltd. includes tables with up to 10-years of history of computed ratios, sales, earnings, and security prices.